Trial Profile
Longitudinal non-interventional observational study on Adherence, safety and tolerability of AVANZ in adults and GRAZAX and SLIToneULTRA in adults and children (5 - 17 years) in patients with allergic Rhinoconjunctivitis in GErmany - LARGE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2018
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary) ; House dust mite allergy immunotherapy-ALK Abello (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms LARGE
- Sponsors ALK-Abello
- 05 Nov 2018 Status changed from active, no longer recruiting to completed.
- 20 Jan 2015 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2014 Status changed from not yet recruiting to recruiting, according to German Clinical Trials Register record.